We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting

By LabMedica International staff writers
Posted on 17 Oct 2022

The fastest SARS-CoV-2 antigen test, that offers a reliable and easy-to-use testing solution for COVID-19 infection, is now available in Europe and any countries accepting the CE mark. More...

MedMira Inc. (Halifax, NS, Canada) has developed its first rapid antigen test, the VYRA COVID-19 Antigen Test (VYRA COVID-19), utilizing its patented Rapid Vertical Flow (RVF) technology. The technology facilitates the formation of highly specific antigen-antibody reactions allowing specific biomarkers in many sample types, including human whole blood, serum or plasma, to be captured and visualized on a unique membrane. The simple test procedure involves adding the specimen to the device and allowing it to flow through the membrane. If the specimen contains the target antibodies or antigens, they are captured on the test membrane and can be visually interpreted immediately after the addition of a detection reagent. The technology platform is unique in its ability to detect multiple biomarkers specific to several diseases using a single cartridge.

VYRA COVID-19, built using MedMira’s RVF technology, detects antigens specific for the nucleocapsid region of SARS-CoV-2, the causative agent of COVID-19, and can determine an active infection in less than three minutes. VYRA COVID-19 nasal swab based test is designed to be non-invasive and user-friendly, making it more suitable for any setting. Designed to detect SARS-CoV-2 virus in swab samples, VYRA COVID-19 directly addresses the need for a fast, reliable, and easy-to-use testing solution. MedMira has received the CE mark for its VYRA COVID-19, which is now the fastest SARS-CoV-2 antigen test available.

"Whereas VYRA COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a COVID-19 infection, our up-coming VYRA CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for COVID-19 or Flu A or Flu B immediately," said Hermes Chan, CEO of MedMira Inc. "With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira's VYRA COVID-19 is the fastest and most reliable answer. We anticipate our CE mark for the VYRA CoV2Flu and REVEALCOVID-19 Nab-Y Neutralizing Antibody Test in the coming weeks and with it are able to offer our distribution partners a complete set of COVID-19 related products."

Related Links:
MedMira


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.